论文部分内容阅读
血管紧张素转化酶抑制剂(ACEI)可改善运动耐力,提高心衰病人生活质量和生存率。卡托普利(Captopril)和依那普利(enalapril)已被批准用于心衰的治疗。尽管两者作用持续时间及副作用不同,但通常认为任何一种ACEI效果均相同。最近,Pouleur等对以扎莫特罗(Xamoterol系β受体部分激动剂—译者)为基础治疗患者死亡率进行回顾性分析发现:加用Captopril者死亡率明显高于加用enalapril者,
Angiotensin converting enzyme inhibitor (ACEI) can improve exercise tolerance and improve the quality of life and survival of patients with heart failure. Captopril and enalapril have been approved for the treatment of heart failure. Although both duration of action and side effects are different, it is generally accepted that the effect of any one of the ACEIs is the same. Recently, Pouleur et al retrospectively analyzed the mortality of patients treated with Zamterol (a partial agonist of the Xamoterol system) and found that the mortality rate was significantly higher with addition of Captopril than with enalapril,